Search
Hengrui Medicine Receives Orphan Drug Designation from US FDA
2025-08-06 /
Read about 0 minute
Author：小编
Hengrui Medicine has announced that its combination therapy, comprising a recombinant anti-HER2 humanized monoclonal antibody injection alongside adebelizumab injection and chemotherapy, has been awarded Orphan Drug Designation by the US Food and Drug Administration (FDA) for the treatment of gastric cancer or adenocarcinoma of the gastroesophageal junction. This prestigious designation will provide Hengrui Medicine with access to a range of supportive US policies, encompassing product research and development, registration, and commercialization.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
